Phase 3 Recruiting Network
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medicat…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05929768
Sites in Virginia: - University of Virginia Cancer Center — Charlottesville, Virginia
- Bon Secours Memorial Regional Medical Center — Mechanicsville, Virginia
- Bon Secours Westchester Emergency Center — Midlothian, Virginia
- Bon Secours Saint Francis Medical Center — Midlothian, Virginia
- Bon Secours Richmond Community Hospital — Richmond, Virginia
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of continuation of treatment with pembrolizumab (usual approach) to observation only at preventing cancer from coming back in patients with early-stage triple-negative breast cancer (TNBC) who achie…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05812807
Sites in Virginia: - Inova Schar Cancer Institute — Fairfax, Virginia
- Inova Fair Oaks Hospital — Fairfax, Virginia
- Inova Fairfax Hospital — Falls Church, Virginia
- Augusta Health Center for Cancer and Blood Disorders — Fishersville, Virginia
- Centra Alan B Pearson Regional Cancer Center — Lynchburg, Virginia
Phase 3 Recruiting Network
This trial has two cohorts of patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. All patients must be receiving trastuzumab-based treatment. Both cohorts are bei…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03418961
Sites in Virginia: - Augusta Health Center for Cancer and Blood Disorders — Fishersville, Virginia
Phase 3 Recruiting NIH
This phase III trial compares standard of care hormone therapy plus ribociclib to chemotherapy followed by hormone therapy plus ribociclib for the treatment of patients with high anatomic stage breast cancer with low risk of the cancer ret…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07391774
Sites in Virginia: - Augusta Health Center for Cancer and Blood Disorders — Fishersville, Virginia
- Centra Alan B Pearson Regional Cancer Center — Lynchburg, Virginia
- Bon Secours Memorial Regional Medical Center — Mechanicsville, Virginia
- Bon Secours Saint Francis Medical Center — Midlothian, Virginia
- Bon Secours Richmond Community Hospital — Richmond, Virginia
Phase 3 Recruiting Industry
The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which inc…
Sponsor: Gilead Sciences
NCT ID: NCT05633654
Sites in Virginia: - University of Virginia — Charlottesville, Virginia
- Inova Fairfax Hospital — Fairfax, Virginia
- Bon Secours Cancer Institute at St. Francis — Midlothian, Virginia
- Virginia Commonwealth University Medical Center — Richmond, Virginia
- Oncology and Hematology Associates of Southwest Virginia, Inc — Wytheville, Virginia
Phase 3 Recruiting Industry
This is a randomized, open-label study comparing the efficacy and safety of adjuvant sacituzumab tirumotecan (MK-2870) in combination with pembrolizumab compared to treatment of physician's choice (TPC) in participants with triple-negative…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06393374
Sites in Virginia: - Mary Washington Hospital ( Site 0129) — Fredericksburg, Virginia
- Hematology Oncology Associates of Fredericksburg ( Site 9550) — Fredericksburg, Virginia
- Bon Secours Memorial Regional Medical Center-Oncology Research Department ( Site 0020) — Midlothian, Virginia
- Virginia Oncology Associates (VOA) ( Site 8008) — Norfolk, Virginia
- Virginia Cancer Institute ( Site 0034) — Richmond, Virginia
Phase 3 Recruiting Industry
This is a multicenter randomized, open label study to evaluate overall survival with the Bria-IMT regimen in combination with Checkpoint Inhibitor \[Retifanlimab\], versus Treatment of Patients'/Physicians' Choice (TPC) in advanced metasta…
Sponsor: BriaCell Therapeutics Corporation
NCT ID: NCT06072612
Sites in Virginia: - Hematology-Oncology Associates of Fredericksburg, Inc — Fredericksburg, Virginia
Phase 3 Recruiting Network
This phase III trial evaluates the effect of adding locoregional therapy (surgery and radiation) and metastasis-directed stereotactic body radiation therapy (SBRT) to standard systemic therapy following standard HER2-targeted systemic ther…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT07578116
Sites in Virginia: - Bon Secours Memorial Regional Medical Center — Mechanicsville, Virginia
- Bon Secours Saint Francis Medical Center — Midlothian, Virginia
- Bon Secours Saint Mary's Hospital — Richmond, Virginia
- Bon Secours Cancer Institute at Reynolds Crossing — Richmond, Virginia
Phase 2, Phase 3 Recruiting Industry
The purpose of this study is to assess the efficacy and safety of iza-bren, a bi-specific antibody-drug conjugate against EGFR and HER3 with a topoisomerase inhibitor payload versus treatment of physician's choice (TPC) (paclitaxel, nab-pa…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT06926868
Sites in Virginia: - Bon Secours St. Francis Medical Center — Midlothian, Virginia
- Local Institution - 0301 — Roanoke, Virginia
- Shenandoah Oncology, P.C. — Winchester, Virginia
Phase 3 Recruiting Industry
The purpose of the study is to demonstrate superiority of Saruparib (AZD5305) relative to placebo added to a standard radiation therapy (RT) + androgen deprivation therapy (ADT) regimen by assessment of metastases-free survival in particip…
Sponsor: AstraZeneca
NCT ID: NCT06952803
Sites in Virginia: - Research Site — Norfolk, Virginia
- Research Site — Roanoke, Virginia
- Research Site — Virginia Beach, Virginia
Phase 2 Recruiting Academic/Other
The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which types of breast cancer tumors and by learning more about which early indicators o…
Sponsor: QuantumLeap Healthcare Collaborative
NCT ID: NCT01042379
Sites in Virginia: - Inova Health System — Falls Church, Virginia
Phase 2 Recruiting Industry
This study will include two groups of patients: Cohort 1 and Cohort 2. Cohort 1: will help researchers learn how a medicine called imlunestrant (LY3484356) affects a specific type of breast cancer. Some patients will take both imlunestrant…
Sponsor: Eli Lilly and Company
NCT ID: NCT07287098
Sites in Virginia: - University of Virginia Health System — Charlottesville, Virginia
- Inova Schar Cancer Institute — Fairfax, Virginia
Phase 1, Phase 2 Recruiting Industry
This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) o…
Sponsor: Genmab
NCT ID: NCT05579366
Sites in Virginia: - USOR Virginia Cancer Specialists — Fairfax, Virginia
- USOR Virginia Oncology Associates — Norfolk, Virginia
Phase 1, Phase 2 Recruiting Industry
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1303/BNT323 in subjects with advanced solid tumors that express HER2.
Sponsor: DualityBio Inc.
NCT ID: NCT05150691
Sites in Virginia: - NEXT Virginia — Fairfax, Virginia
Phase 2 Recruiting Industry
PUMA-ALI-1201 is a randomized, dose optimization, multicenter, Phase 2 study of alisertib administered in combination with endocrine therapy in participants with pathology-confirmed HR-positive/HER2-negative metastatic breast cancer (MBC) …
Sponsor: Puma Biotechnology, Inc.
NCT ID: NCT06369285
Sites in Virginia: - Virginia Cancer Institute — Richmond, Virginia
Phase 1, Phase 2 Recruiting Industry
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…
Sponsor: PMV Pharmaceuticals, Inc
NCT ID: NCT04585750
Sites in Virginia: - Virginia Cancer Specialists — Fairfax, Virginia
Phase 2 Recruiting Academic/Other
The goal of this trial is to see if active surveillance monitoring and hormonal therapy in patients diagnosed with ductal cell carcinoma in situ (DCIS), an early stage of breast cancer, can be an effective management of the disease. Partic…
Sponsor: QuantumLeap Healthcare Collaborative
NCT ID: NCT06075953
Sites in Virginia: - Virginia Commonwealth University — Richmond, Virginia
Phase 2 Recruiting Industry
The Substudy Protocol ASPEN-09-03 is a Phase 2, single-arm, multicenter study evaluating the efficacy, safety, and tolerability of evorpacept in combination with trastuzumab and chemotherapy in participants with HER2-positive metastatic br…
Sponsor: ALX Oncology Inc.
NCT ID: NCT07007559
Sites in Virginia: - Virginia Cancer Specialists — Fairfax, Virginia
Phase 1, Phase 2 Recruiting Industry
This study, the first clinical trial of AVZO-023, aims to determine the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, maximum tolerated dose, and anti-tumor effects of AVZO-023 in patients with advanced solid tumors. AVZO-…
Sponsor: Avenzo Therapeutics, Inc.
NCT ID: NCT06998407
Sites in Virginia: - Avenzo Therapeutics Recruiting Site — Fairfax, Virginia
Phase 1, Phase 2 Recruiting Industry
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1310 in subjects with advanced solid tumors.
Sponsor: DualityBio Inc.
NCT ID: NCT05785741
Sites in Virginia: - NEXT Virginia — Fairfax, Virginia
Phase 1, Phase 2 Recruiting Industry
The goal of this study is to identify a safe and tolerated dose of the orally administered KIF18A inhibitor ATX-295. In addition, this study will evaluate the pharmacokinetics, pharmacodynamics and preliminary antitumor activity of ATX-295…
Sponsor: Accent Therapeutics
NCT ID: NCT06799065
Sites in Virginia: - NEXT Virginia — Fairfax, Virginia
Phase 1, Phase 2 Recruiting Industry
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
Sponsor: AstraZeneca
NCT ID: NCT07115043
Sites in Virginia: - Research Site — Fairfax, Virginia
Phase 1, Phase 2 Recruiting Industry
Study ATX-898-101 is a phase 1/2 open-label study evaluating the safety, tolerability, pharmacokinetic, and preliminary efficacy of ATX-898 as monotherapy and in combination with anti-neoplastic agents in selected solid tumors. This study …
Sponsor: Antares Therapeutics, Inc
NCT ID: NCT07767474
Sites in Virginia: - NEXT Virginia Cancer Center- Merrifield Tech Center — Fairfax, Virginia
Phase 1, Phase 2 Recruiting Industry
Specific proteins found in tumors help the tumors spread and grow. People with solid tumors often have a protein called TROP2 in their tumor. ASP2998 is being developed to attach to TROP2 and then attack the tumor cells in people with soli…
Sponsor: Astellas Pharma Global Development, Inc.
NCT ID: NCT07287995
Sites in Virginia: - NEXT Virginia — Fairfax, Virginia
Phase 1, Phase 2 Recruiting Academic/Other
The purpose of this study is to understand the safety and estimate the efficacy of anti-CD3 x anti-HER2 bispecific antibody (HER2Bi) armed fresh peripheral blood mononuclear cells (HER2 FPBMC) for patients with metastatic breast or prostat…
Sponsor: University of Virginia
NCT ID: NCT07441889
Sites in Virginia: - University of Virginia — Charlottesville, Virginia